Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | POLLUX & CASTOR analysis: MRD- with dara-combination regimens

Sagar Lonial • 11 Mar 2021
EMN 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide
CASTOR POLLUX

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the results of an analysis of measurable residual disease (MRD) negativity with daratumumab (dara)-combination regimens using data from the POLLUX (NCT02076009) and CASTOR (NCT02136134) trials. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Disclosures

Sagar Lonial, MD, has done consultancy work for Janssen, Takeda, Amgen, Celgene, Novartis, GSK, Pfizer, ABBVIE, and BMS.

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals